BR9808513A - Composto, composição farmacêutica, método para tratamento de infecções por hiv e kit farmacêutico. - Google Patents

Composto, composição farmacêutica, método para tratamento de infecções por hiv e kit farmacêutico.

Info

Publication number
BR9808513A
BR9808513A BR9808513-1A BR9808513A BR9808513A BR 9808513 A BR9808513 A BR 9808513A BR 9808513 A BR9808513 A BR 9808513A BR 9808513 A BR9808513 A BR 9808513A
Authority
BR
Brazil
Prior art keywords
pharmaceutical
compound
treating hiv
pharmaceutical composition
hiv infections
Prior art date
Application number
BR9808513-1A
Other languages
English (en)
Inventor
Jeffrey W Corbett
Soo Sung Ko
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of BR9808513A publication Critical patent/BR9808513A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<B>"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO PARA TRATAMENTO DE INFECçõES POR HIV E KIT FARMACêUTICO"<D> A presente invenção se refere a 3,4-di-hidro-2(1H)-quinazolinonas 4,4-dissubstituídas da fórmula (I), ou suas formas estereoisoméricas, misturas estereoisoméricas ou formas de sais aceitáveis para uso farmacêutico, que sejam úteis como inibidores de transcriptase reversa de HIV e composições farmacêuticas e "kits"de diagnóstico compreendendo estas últimas, bem como métodos de utilização de tais composições para o tratamento de infecções virais ou como padrão de ensaio ou reagente.
BR9808513-1A 1997-04-09 1998-04-07 Composto, composição farmacêutica, método para tratamento de infecções por hiv e kit farmacêutico. BR9808513A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83854097A 1997-04-09 1997-04-09
US7132298P 1998-01-14 1998-01-14
PCT/US1998/006733 WO1998045276A2 (en) 1997-04-09 1998-04-07 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
BR9808513A true BR9808513A (pt) 2000-05-23

Family

ID=26752095

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808513-1A BR9808513A (pt) 1997-04-09 1998-04-07 Composto, composição farmacêutica, método para tratamento de infecções por hiv e kit farmacêutico.

Country Status (19)

Country Link
EP (1) EP0973753A2 (pt)
JP (1) JP2002504095A (pt)
KR (1) KR20010006146A (pt)
CN (1) CN1252063A (pt)
AR (1) AR012340A1 (pt)
AU (1) AU734928B2 (pt)
BR (1) BR9808513A (pt)
CA (1) CA2284996A1 (pt)
EA (1) EA001991B1 (pt)
EE (1) EE9900452A (pt)
HR (1) HRP980143A2 (pt)
HU (1) HUP0001446A3 (pt)
IL (1) IL132188A0 (pt)
NO (1) NO314936B1 (pt)
NZ (1) NZ500592A (pt)
PL (1) PL336305A1 (pt)
SK (1) SK137899A3 (pt)
TW (1) TW587078B (pt)
WO (1) WO1998045276A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509922A (ja) * 1998-03-27 2002-04-02 デュポン ファーマシューティカルズ カンパニー ４，４−二置換−３，４−ジヒドロ−２（１ｈ）−キナゾリンチオン誘導体、それらの調製法、およびｈｉｖ逆転写酵素阻害剤としてのそれらの使用
AU6508899A (en) 1998-10-13 2000-05-01 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
AU1821900A (en) * 1998-11-19 2000-06-05 Du Pont Pharmaceuticals Company Process for the preparation of quinazolinones
WO2000029390A1 (en) * 1998-11-19 2000-05-25 Du Pont Pharmaceuticals Company Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro- 2(1h)-quinazolinone
US6175009B1 (en) 1999-11-18 2001-01-16 Dupont Pharmaceuticals Company Process for the preparation of quinazolinones
DE60023025T2 (de) * 1999-11-23 2006-07-13 Smithkline Beecham Corp. 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
CA2403230A1 (en) * 2000-03-23 2001-09-27 Lilian A. Radesca Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
US6555686B2 (en) * 2000-03-23 2003-04-29 Bristol-Myers Squibb Pharma Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US6596729B2 (en) 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7713214B2 (en) 2002-04-19 2010-05-11 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
EP1575583A1 (en) * 2002-12-16 2005-09-21 Boehringer Ingelheim Pharmaceuticals Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc METHOD AND APPARATUS PROVIDING A VARIABLE USER INTERFACE
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH &amp; Co. KG Printable hydrogel for biosensors
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc METHOD AND APPARATUS FOR MANUFACTURING A DEVICE FOR SAMPLING LIQUIDS
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102060786A (zh) * 2011-01-20 2011-05-18 天津大学 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用
DK2694101T3 (en) * 2011-04-06 2017-01-09 Biovaxim Ltd Pharmaceutical compositions for the prevention and / or treatment of HIV disease in humans
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9890166B2 (en) 2013-05-27 2018-02-13 Novartis Ag Imidazopyrrolidine derivatives and their use in the treatment of disease
EA028175B1 (ru) 2013-05-28 2017-10-31 Новартис Аг Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
AU2014272700B2 (en) 2013-05-28 2016-12-01 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
EA029269B1 (ru) 2013-11-21 2018-02-28 Новартис Аг Производные пирролопирролона и их применение для лечения заболеваний

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
WO1993022292A1 (en) * 1992-05-07 1993-11-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5663169A (en) * 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4320347A1 (de) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone

Also Published As

Publication number Publication date
EE9900452A (et) 2000-04-17
SK137899A3 (en) 2000-05-16
NO994904L (no) 1999-12-01
EP0973753A2 (en) 2000-01-26
HUP0001446A3 (en) 2001-11-28
HUP0001446A2 (hu) 2001-05-28
HRP980143A2 (en) 1999-02-28
JP2002504095A (ja) 2002-02-05
KR20010006146A (ko) 2001-01-26
IL132188A0 (en) 2001-03-19
PL336305A1 (en) 2000-06-19
TW587078B (en) 2004-05-11
WO1998045276A3 (en) 1999-01-14
AR012340A1 (es) 2000-10-18
CA2284996A1 (en) 1998-10-15
WO1998045276A2 (en) 1998-10-15
EA001991B1 (ru) 2001-10-22
EA199900907A1 (ru) 2000-04-24
NZ500592A (en) 2001-09-28
AU6796098A (en) 1998-10-30
AU734928B2 (en) 2001-06-28
NO994904D0 (no) 1999-10-08
CN1252063A (zh) 2000-05-03
NO314936B1 (no) 2003-06-16

Similar Documents

Publication Publication Date Title
BR9808513A (pt) Composto, composição farmacêutica, método para tratamento de infecções por hiv e kit farmacêutico.
BR0015056A (pt) Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
BR9917080A (pt) Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
BRPI0212726B8 (pt) compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos
BRPI0418639B8 (pt) compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos
BR0209271A (pt) Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
BR0113039A (pt) Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
BRPI0408767B8 (pt) inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica
BR0208987A (pt) Composto tricìclicos úteis como inibidores de transcriptase reserva de hiv
BR0306927A (pt) Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv
BR9916255A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento de uma condição em que se requer inibição de trombina e para a preparação de compostos
WO2004002410A3 (en) 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
BR0015333A (pt) Derivados de isoxazol como inibidores de fosfodiesterase vii
BR9814933A (pt) Composto, composicao farmaceutica e metodo de tratamento de infeccao por hiv.
BRPI0414199A (pt) inibidores de entrada do vìrus hiv
LT2003003A (en) Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors
BR0314709A (pt) Derivados de pirazol
DE50109698D1 (de) N-heteroarylmethyl-m-phenylendiamin-derivate enthaltende färbemittel für keratinfasern sowie neue n-heteroarylmethyl-m-phenylendiamin-derivate
BR9712910A (pt) ra o tratamento de infecção por hiv
BRPI0012329B8 (pt) derivados de benzofurano, processo para sua preparação e uso dos mesmos.
BR9712755A (pt) Composto, composição farmacêutica, método para o tratamento de infecção por hiv e kit farmacêutico útil para o tratamento de infecção por hiv
BRPI0412253A (pt) derivados de nicotinamida úteis como inibidores de pde4

Legal Events

Date Code Title Description
TE Change of address
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1889 DE 20/03/2007.